Methoxychlor (MXC) and its metabolites bind to estrogen receptors (ESRs) and increase ovarian atresia. To test whether ESR alpha (ESR1) overexpressing (ESR1 OE) antral follicles are more sensitive to atresia compared to controls, we cultured antral follicles with vehicle, MXC (1-100 μg/ml) or metabolites (0.1-10 μg/ml). Results indicate that MXC and its metabolites significantly increase atresia in ESR1 OE antral follicles at lower doses compared to controls. Activity of pro-apoptotic factor caspase-3/7 was significantly higher in ESR1 OE treated antral follicles compared to controls. ESR1 OE mice dosed with MXC 64 mg/kg/day had an increased percentage of atretic antral follicles compared to controls. Furthermore, pro-caspase-3 levels were found to be significantly lower in ESR1 OE ovaries than controls dosed with MXC 64 mg/kg/day. These data suggest that ESR1 OE ovaries are more sensitive to atresia induced by MXC and its metabolites in vitro and in vivo compared to controls.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327814 | PMC |
| http://dx.doi.org/10.1016/j.reprotox.2012.01.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
LncRNA-THBS4 affects granulosa cell proliferation and apoptosis in diminished ovarian reserve by regulating PI3K/AKT/mTOR signaling pathway.
J Reprod Immunol
December 2024
School of Medical and Life Sciences/Reproductive &Women-Children Hospital, Chengdu University of Traditional Chinese Medicine, No.1166 Liutai Avenue, Wenjiang District, Chengdu, Sichuan Province 611137, China; Chengdu Fifth People's Hospital, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine. Electronic address:
Backgrounds: Recent studies have found Several lncRNAs were proved differential expression in diminished ovarian reserve (DOR) patients, however, the mechanism of DOR caused by lncRNAs is still largely unclear.
Methods: High throughput sequencing was performed in ovarian GCs extracted from women with normal ovarian function and women with DOR. Bioinformation analysis was used to analyze the sequencing data and identify the differential expression of lncRNAs.
Assessment of ovarian reserve function in patients with adenomyosis and ovarian endometriosis by three-dimensional transvaginal ultrasound and Anti-Müllerian hormone.
Sci Rep
December 2024
Department of Ultrasonography, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
We evaluated the impact of adenomyosis and ovarian endometriosis on ovarian reserve function through transvaginal three-dimensional ultrasound and anti-mullerian hormone testing. A total of 150 female patients who were admitted to our hospital from January 2023 to May 2024 were selected; 58 cases had adenomyosis (adenomyosis group), 36 had ovarian endometriosis (ovarian endometriosis group), and 56 were healthy (healthy group). There were no statistically significant differences in clinical baseline data among the three groups (all P > 0.
View Article and Find Full Text PDFFlexible progestin-primed ovarian stimulation versus a GnRH antagonist protocol in predicted suboptimal responders undergoing freeze-all cycles: a randomized non-inferiority trial.
Hum Reprod
December 2024
Assisted Reproduction Center, Northwest Women's and Children's Hospital, Xi'an, China.
Study Question: Are live birth rates (LBRs) per woman following flexible progestin-primed ovarian stimulation (fPPOS) treatment non-inferior to LBRs per woman following the conventional GnRH-antagonist protocol in expected suboptimal responders undergoing freeze-all cycles in assisted reproduction treatment?
Summary Answer: In women expected to have a suboptimal response, the 12-month likelihood of live birth with the fPPOS treatment did not achieve the non-inferiority criteria when compared to the standard GnRH antagonist protocol for IVF/ICSI treatment with a freeze-all strategy.
What Is Known Already: The standard PPOS protocol is effective for ovarian stimulation, where medroxyprogesterone acetate (MPA) is conventionally administered in the early follicular phase for ovulatory suppression. Recent retrospective cohort studies on donor cycles have shown the potential to prevent premature ovulation and maintain oocyte yields by delaying the administration of MPA until the midcycle (referred to as fPPOS), similar to GnRH antagonist injections.
INTEGRATED MANAGEMENT OF OVARIAN ENDOMETRIOMAS: PRE- AND POST-SURGICAL USE OF DIENOGEST.
Georgian Med News
October 2024
2Department of Reproductology and Obstetrics and Gynecology, I. Javakhishvili Tbilisi State University; 3Prof. Zhordania and Prof. Khomasuridze Institute of Reproductology, Tbilisi, Georgia.
Aim: to evaluate the efficacy of an integrated management approach for ovarian endometriomas using Dienogest administered both before and after laparoscopic cyst enucleation in women with infertility.
Materials And Methods: The prospective, comparative clinical trial included 44 patients aged 18-35 years with ovarian endometriomas and infertility. Patients were randomly divided into two groups: the study group (20 participants) received Dienogest for six months before and after laparoscopic cyst enucleation, while the control group (24 participants) underwent laparoscopic cyst enucleation without additional hormonal treatment.
Promotes Follicle Growth Through the PI3K/AKT Signaling Pathway In Vivo and In Vitro in Rat.
Food Sci Nutr
December 2024
Key Laboratory of TCM Pharmacology Jilin Academy of Chinese Medicine Sciences Changchun Jilin P.R. China.
The development status of follicles determines the menstrual cycle and estrogen levels, which is crucial to women's health. is a natural product for both medicine and food, which has "estrogenic effect". However, few studies have systematically elaborated its mechanism of action.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!